Adverum Biotechnologies (ADVM) Competitors $2.97 +0.04 (+1.37%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$2.96 -0.01 (-0.20%) As of 08/22/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADVM vs. SGMT, SOPH, AARD, FENC, TLSA, GALT, ALEC, TVRD, MNPR, and CRGXShould you be buying Adverum Biotechnologies stock or one of its competitors? The main competitors of Adverum Biotechnologies include Sagimet Biosciences (SGMT), SOPHiA GENETICS (SOPH), Aardvark Therapeutics (AARD), Adherex Technologies (FENC), Tiziana Life Sciences (TLSA), Galectin Therapeutics (GALT), Alector (ALEC), Tvardi Therapeutics (TVRD), Monopar Therapeutics (MNPR), and CARGO Therapeutics (CRGX). These companies are all part of the "pharmaceutical products" industry. Adverum Biotechnologies vs. Its Competitors Sagimet Biosciences SOPHiA GENETICS Aardvark Therapeutics Adherex Technologies Tiziana Life Sciences Galectin Therapeutics Alector Tvardi Therapeutics Monopar Therapeutics CARGO Therapeutics Adverum Biotechnologies (NASDAQ:ADVM) and Sagimet Biosciences (NASDAQ:SGMT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability. Which has more risk & volatility, ADVM or SGMT? Adverum Biotechnologies has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Sagimet Biosciences has a beta of 3.37, meaning that its stock price is 237% more volatile than the S&P 500. Is ADVM or SGMT more profitable? Sagimet Biosciences' return on equity of -39.88% beat Adverum Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adverum BiotechnologiesN/A -297.29% -101.40% Sagimet Biosciences N/A -39.88%-38.40% Do analysts recommend ADVM or SGMT? Adverum Biotechnologies presently has a consensus price target of $19.75, suggesting a potential upside of 564.98%. Sagimet Biosciences has a consensus price target of $25.67, suggesting a potential upside of 260.99%. Given Adverum Biotechnologies' higher possible upside, analysts clearly believe Adverum Biotechnologies is more favorable than Sagimet Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adverum Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Sagimet Biosciences 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, ADVM or SGMT? Sagimet Biosciences has higher revenue and earnings than Adverum Biotechnologies. Sagimet Biosciences is trading at a lower price-to-earnings ratio than Adverum Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdverum Biotechnologies$1M62.32-$130.93M-$7.85-0.38Sagimet Biosciences$2M109.03-$45.57M-$1.83-3.89 Do institutionals & insiders have more ownership in ADVM or SGMT? 48.2% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 87.9% of Sagimet Biosciences shares are held by institutional investors. 6.0% of Adverum Biotechnologies shares are held by insiders. Comparatively, 14.7% of Sagimet Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the media favor ADVM or SGMT? In the previous week, Adverum Biotechnologies had 3 more articles in the media than Sagimet Biosciences. MarketBeat recorded 5 mentions for Adverum Biotechnologies and 2 mentions for Sagimet Biosciences. Sagimet Biosciences' average media sentiment score of 0.57 beat Adverum Biotechnologies' score of 0.22 indicating that Sagimet Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adverum Biotechnologies 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sagimet Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySagimet Biosciences beats Adverum Biotechnologies on 12 of the 15 factors compared between the two stocks. Get Adverum Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADVM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADVM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADVM vs. The Competition Export to ExcelMetricAdverum BiotechnologiesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.32M$3.11B$5.81B$9.76BDividend YieldN/A2.23%4.39%4.06%P/E Ratio-0.3821.0031.3626.05Price / Sales62.32209.44387.8788.42Price / CashN/A44.5038.0259.36Price / Book-3.098.129.536.60Net Income-$130.93M-$54.72M$3.26B$265.65M7 Day Performance3.85%2.62%2.14%2.00%1 Month Performance11.24%3.25%3.22%0.46%1 Year Performance-59.43%10.82%30.18%18.88% Adverum Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADVMAdverum Biotechnologies3.9185 of 5 stars$2.97+1.4%$19.75+565.0%-59.4%$62.32M$1M-0.38190SGMTSagimet Biosciences2.8982 of 5 stars$7.55-1.6%$25.67+240.0%+141.8%$235.28M$2M-4.138SOPHSOPHiA GENETICS2.946 of 5 stars$3.49+0.6%$8.00+129.2%-3.5%$234.50M$65.17M-7.93520Positive NewsGap UpAARDAardvark TherapeuticsN/A$10.44-3.2%$32.80+214.2%N/A$233.89MN/A0.0018News CoverageAnalyst RevisionFENCAdherex Technologies1.7796 of 5 stars$8.20-1.9%$13.33+62.6%+51.9%$232.52M$47.54M-19.5210News CoverageAnalyst ForecastAnalyst RevisionTLSATiziana Life Sciences0.5515 of 5 stars$1.89-4.1%N/A+68.9%$230.19MN/A0.008GALTGalectin Therapeutics2.4019 of 5 stars$3.90+9.2%$6.00+53.8%+77.5%$228.70MN/A-6.099ALECAlector3.8955 of 5 stars$2.13-5.3%$4.17+95.6%-52.5%$227.73M$100.56M-1.84270TVRDTvardi Therapeutics1.5448 of 5 stars$24.74+3.1%$64.25+159.7%N/A$224.66M$7.14M0.0080News CoverageMNPRMonopar Therapeutics2.7295 of 5 stars$34.26-4.1%$60.00+75.1%+1,137.8%$220.33MN/A-10.2910CRGXCARGO Therapeutics2.0149 of 5 stars$4.47-1.5%$15.40+244.5%N/A$219.57MN/A-0.96116News CoverageAnalyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies SGMT Alternatives SOPH Alternatives AARD Alternatives FENC Alternatives TLSA Alternatives GALT Alternatives ALEC Alternatives TVRD Alternatives MNPR Alternatives CRGX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADVM) was last updated on 8/24/2025 by MarketBeat.com Staff From Our PartnersTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adverum Biotechnologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adverum Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access